Evidence map›Paper›PMID 38129988›Full record

ArticleClinical and translational science2023

Pharmacokinetics of Dacarbazine and Unesbulin and CYP1A2-Mediated Drug Interactions in Patients With Leiomyosarcoma.

Lan Gao, Diksha Kaushik, Brian A Van Tine, Matthew A Ingham, Steven Attia, Christian F Meyer, Gary K Schwartz, Pius Maliakal, John D Baird, Jiyuan Ma and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Lan GaoPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.ORCID https://orcid.org/0000-0002-2528-7656
Diksha KaushikPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Brian A Van TineDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Matthew A InghamColumbia University Medical Center, New York, NY, USA.
Steven AttiaMayo Clinic, Jacksonville, FL, USA.
Christian F MeyerJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Gary K SchwartzColumbia University Medical Center, New York, NY, USA.
Pius MaliakalPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
John D BairdPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Jiyuan MaPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Rosemary BarrettPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Dhiren D'SilvaPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Kylie O'KeefePTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
Ronald KongPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, USA.
PTC Therapeutics (United States) · USColumbia University Irving Medical Center · USJacksonville College · USSidney Kimmel Comprehensive Cancer Center · USSt. Louis Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surrogate metabolite 5-aminoimidazole-4-carboxamide (AIC) in 29 patients with advanced LMS. Drug interactions between DTIC (and AIC) and unesbulin were evaluated. DTIC (1000 mg/m

Identifiers

PMID38129988
PMCPMC10825620
OpenAlexW4390110435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.